NVA-237 shows efficacy in GLOW trials and is filed for marketing as COPD therapy in E.U. Oct. 6, 2011
Evaluation of kynurenine 3-monooxygenase as target for Huntington's disease therapy advances Oct. 6, 2011
RSS